Tuesday, 25 February 2014

Bevacizumab fails to improve overall survival in first-line treatment for glioblastoma

The February 20, 2014 issue of The New England Journal of Medicine features the results of two well-conducted, placebo-controlled, randomised trials: the Avastin in Glioblastoma (AVAglio) trial and the Radiation Therapy Oncology Group (RTOG) 0825 trial. Both studies address the clinical benefit of adding bevacizumab to the best standard treatment for newly-diagnosed glioblastoma (radiotherapy/temozolomide). Read more here.

No comments:

Post a Comment